FCB Business Summary

Feng Chi Biotech Corp. (FCB), trading as 6744.TWO on the Taipei Exchange, operates a dual-revenue model centered on the distribution of advanced medical instrumentation and the provision of specialized biotechnology services. The company generates significant revenue as the exclusive Taiwan distributor for high-throughput genomic platforms, notably the Agena MassARRAY system and ArcherDX NGS library kits. Its primary business segments include Genetic Testing Services—covering preimplantation genetic testing (PGT), non-invasive prenatal testing (NIPT), and oncology screening—and Life Science Research, which provides translational research and microbiological testing for the pharmaceutical and food industries. FCB maintains a specialized market niche by combining proprietary diagnostic services with the sale of high-margin reagents and equipment maintenance contracts. Leadership is spearheaded by Chairman and CEO Hong-Ming Zhang (also known as Hong-Ming Chang), who founded the company in 1992 and has overseen its evolution from a medical equipment trader into a comprehensive genomic diagnostics provider. The executive team is characterized by deep technical expertise in molecular biology and clinical diagnostics, focusing on precision medicine and personalized treatment strategies. While the company operates with a lean management structure, its board includes strategic representation from domestic investment firms such as Chiu Chiang Investment. FCB competes directly with other Taiwan-based genomic leaders, including Genomics BioSci & Tech (3164.TWO), GGA Corp (6658.TWO), and Pharmigene (6425.TWO), positioning itself as a key intermediary between global technology providers and local clinical institutions.